GSK: Statement - Zantac Litigation - Kasza Case
June 11, 2024
June 11, 2024
LONDON, England, June 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
GSK plc (LSE/NYSE: GSK) welcomes the plaintiff's voluntary dismissal of the next Zantac case (Kasza), which was scheduled to start trial in Illinois state court on 10 June 2024.
GSK did not settle Ms. Kasza's claim and has not paid anything in exchange for the voluntary dismissal.
Following the 16 epidemiological studies loo . . .
GSK plc (LSE/NYSE: GSK) welcomes the plaintiff's voluntary dismissal of the next Zantac case (Kasza), which was scheduled to start trial in Illinois state court on 10 June 2024.
GSK did not settle Ms. Kasza's claim and has not paid anything in exchange for the voluntary dismissal.
Following the 16 epidemiological studies loo . . .